18F-FDG and 18F-Florbetapir PET in Clinical Practice: Regional Analysis in Mild Cognitive Impairment and Alzheimer Disease. Bailly, M., Ribeiro, M. J. S., Vercouillie, J., Hommet, C., Gissot, V., Camus, V., & Guilloteau, D. Clinical Nuclear Medicine, 40(2):e111--116, February, 2015. doi abstract bibtex OBJECTIVE: The aim of this study is to compare regional cerebral metabolic rate of glucose metabolism and amyloid-β density in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy elderly subjects. METHODS: Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-florbetapir (266 MBq) and F-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software. RESULTS: The mean values of F-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15%, -22%, and -11%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15% and -13% compared with healthy control subjects). Only precuneus cortex showed an increased F-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-β density. CONCLUSIONS: In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-β density in AD. F-florbetapir PET analysis needs to be visual and global, whereas F-FDG analysis can be regional.
@article{bailly_18f-fdg_2015,
title = {18F-{FDG} and 18F-{Florbetapir} {PET} in {Clinical} {Practice}: {Regional} {Analysis} in {Mild} {Cognitive} {Impairment} and {Alzheimer} {Disease}},
volume = {40},
issn = {1536-0229},
shorttitle = {18F-{FDG} and 18F-{Florbetapir} {PET} in {Clinical} {Practice}},
doi = {10.1097/RLU.0000000000000666},
abstract = {OBJECTIVE: The aim of this study is to compare regional cerebral metabolic rate of glucose metabolism and amyloid-β density in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy elderly subjects.
METHODS: Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-florbetapir (266 MBq) and F-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software.
RESULTS: The mean values of F-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15\%, -22\%, and -11\%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15\% and -13\% compared with healthy control subjects). Only precuneus cortex showed an increased F-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-β density.
CONCLUSIONS: In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-β density in AD. F-florbetapir PET analysis needs to be visual and global, whereas F-FDG analysis can be regional.},
language = {eng},
number = {2},
journal = {Clinical Nuclear Medicine},
author = {Bailly, Matthieu and Ribeiro, Maria Joao Santiago and Vercouillie, Johny and Hommet, Caroline and Gissot, Valérie and Camus, Vincent and Guilloteau, Denis},
month = feb,
year = {2015},
pmid = {25549345},
pages = {e111--116}
}
Downloads: 0
{"_id":"YXSS2nNsnBmz5rvTF","bibbaseid":"bailly-ribeiro-vercouillie-hommet-gissot-camus-guilloteau-18ffdgand18fflorbetapirpetinclinicalpracticeregionalanalysisinmildcognitiveimpairmentandalzheimerdisease-2015","downloads":0,"creationDate":"2016-09-29T17:43:10.533Z","title":"18F-FDG and 18F-Florbetapir PET in Clinical Practice: Regional Analysis in Mild Cognitive Impairment and Alzheimer Disease","author_short":["Bailly, M.","Ribeiro, M. J. S.","Vercouillie, J.","Hommet, C.","Gissot, V.","Camus, V.","Guilloteau, D."],"year":2015,"bibtype":"article","biburl":"https://api.zotero.org/groups/96126/items?key=B6W5owjuuUPaKzUaUNIxbwQG&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"18F-FDG and 18F-Florbetapir PET in Clinical Practice: Regional Analysis in Mild Cognitive Impairment and Alzheimer Disease","volume":"40","issn":"1536-0229","shorttitle":"18F-FDG and 18F-Florbetapir PET in Clinical Practice","doi":"10.1097/RLU.0000000000000666","abstract":"OBJECTIVE: The aim of this study is to compare regional cerebral metabolic rate of glucose metabolism and amyloid-β density in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy elderly subjects. METHODS: Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-florbetapir (266 MBq) and F-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software. RESULTS: The mean values of F-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15%, -22%, and -11%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15% and -13% compared with healthy control subjects). Only precuneus cortex showed an increased F-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-β density. CONCLUSIONS: In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-β density in AD. F-florbetapir PET analysis needs to be visual and global, whereas F-FDG analysis can be regional.","language":"eng","number":"2","journal":"Clinical Nuclear Medicine","author":[{"propositions":[],"lastnames":["Bailly"],"firstnames":["Matthieu"],"suffixes":[]},{"propositions":[],"lastnames":["Ribeiro"],"firstnames":["Maria","Joao","Santiago"],"suffixes":[]},{"propositions":[],"lastnames":["Vercouillie"],"firstnames":["Johny"],"suffixes":[]},{"propositions":[],"lastnames":["Hommet"],"firstnames":["Caroline"],"suffixes":[]},{"propositions":[],"lastnames":["Gissot"],"firstnames":["Valérie"],"suffixes":[]},{"propositions":[],"lastnames":["Camus"],"firstnames":["Vincent"],"suffixes":[]},{"propositions":[],"lastnames":["Guilloteau"],"firstnames":["Denis"],"suffixes":[]}],"month":"February","year":"2015","pmid":"25549345","pages":"e111--116","bibtex":"@article{bailly_18f-fdg_2015,\n\ttitle = {18F-{FDG} and 18F-{Florbetapir} {PET} in {Clinical} {Practice}: {Regional} {Analysis} in {Mild} {Cognitive} {Impairment} and {Alzheimer} {Disease}},\n\tvolume = {40},\n\tissn = {1536-0229},\n\tshorttitle = {18F-{FDG} and 18F-{Florbetapir} {PET} in {Clinical} {Practice}},\n\tdoi = {10.1097/RLU.0000000000000666},\n\tabstract = {OBJECTIVE: The aim of this study is to compare regional cerebral metabolic rate of glucose metabolism and amyloid-β density in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy elderly subjects.\nMETHODS: Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-florbetapir (266 MBq) and F-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software.\nRESULTS: The mean values of F-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15\\%, -22\\%, and -11\\%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15\\% and -13\\% compared with healthy control subjects). Only precuneus cortex showed an increased F-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-β density.\nCONCLUSIONS: In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-β density in AD. F-florbetapir PET analysis needs to be visual and global, whereas F-FDG analysis can be regional.},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Clinical Nuclear Medicine},\n\tauthor = {Bailly, Matthieu and Ribeiro, Maria Joao Santiago and Vercouillie, Johny and Hommet, Caroline and Gissot, Valérie and Camus, Vincent and Guilloteau, Denis},\n\tmonth = feb,\n\tyear = {2015},\n\tpmid = {25549345},\n\tpages = {e111--116}\n}\n\n","author_short":["Bailly, M.","Ribeiro, M. J. S.","Vercouillie, J.","Hommet, C.","Gissot, V.","Camus, V.","Guilloteau, D."],"key":"bailly_18f-fdg_2015","id":"bailly_18f-fdg_2015","bibbaseid":"bailly-ribeiro-vercouillie-hommet-gissot-camus-guilloteau-18ffdgand18fflorbetapirpetinclinicalpracticeregionalanalysisinmildcognitiveimpairmentandalzheimerdisease-2015","role":"author","urls":{},"downloads":0},"search_terms":["18f","fdg","18f","florbetapir","pet","clinical","practice","regional","analysis","mild","cognitive","impairment","alzheimer","disease","bailly","ribeiro","vercouillie","hommet","gissot","camus","guilloteau"],"keywords":[],"authorIDs":[],"dataSources":["85HdF3Cu859kHDeZ8"]}